Passage Bio Inc (NASDAQ:PASG) is one of the best gene therapy stocks to buy in 2026. While the stock is down around 50% year-to-date, analysts see it surging 125% over the next 12 months. On April 20, ...

Please note that the posts on The Blogs are contributed by third parties. The opinions, facts and any media content in them are presented solely by the authors, and neither The Times of Israel nor its ...

Fintel reports that on November 12, 2025, Chardan Capital maintained coverage of Passage Bio (NasdaqCM:PASG) with a Buy recommendation. Analyst Price Forecast Suggests 684.87% Upside As of November 9, ...

In an era defined by geopolitical unpredictability and shifting policy landscapes, The Public Affairs Strategies Group (PASG) has officially launched its boutique advisory from India, with ...

Passage Bio, Inc. (PASG Quick Quote PASG - Free Report) closed the last trading session at $7.13, gaining 24.2% over the past four weeks, but there could be plenty of upside left in the stock if short ...

Shares of Passage Bio, Inc. (PASG Quick Quote PASG - Free Report) have gained 31.5% over the past four weeks to close the last trading session at $7.59, but there could still be a solid upside left in ...

In a report released today, Brendan Smith from TD Cowen maintained a Buy rating on Passage Bio. The company’s shares opened today at $5.52. Take advantage of TipRanks Premium at 50% off! Unlock ...

Lynx1 Capital Management L.P., a ten percent owner of Passage Bio, Inc. (NASDAQ: PASG), has increased its stake in the company through a series of purchases. According to a Form 4 filing with the ...

Capital Management LP Lynx1, a 10% owner of $PASG, bought 13,123 shares of the company on 07-22-2025 for an estimated $71,337. This trade was reported by Quiver ...

Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter ...